Comparing ZimVie (NASDAQ:ZIMV) & biote (NASDAQ:BTMD)

ZimVie (NASDAQ:ZIMV) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Earnings & Valuation

This table compares ZimVie and biote”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZimVie	$449.75 million	1.19	-$25.83 million	($0.70)	-27.13
biote	$199.07 million	0.71	$3.16 million	$0.90	3.16

biote has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for ZimVie and biote, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZimVie	1	4	0	0	1.80
biote	0	2	1	0	2.33

ZimVie currently has a consensus price target of $17.75, indicating a potential downside of 6.53%. biote has a consensus price target of $6.00, indicating a potential upside of 111.27%. Given biote’s stronger consensus rating and higher possible upside, analysts clearly believe biote is more favorable than ZimVie.

Institutional and Insider Ownership

95.6% of ZimVie shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 5.4% of ZimVie shares are owned by insiders. Comparatively, 24.0% of biote shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ZimVie and biote’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZimVie	-4.39%	6.37%	3.34%
biote	15.73%	-21.00%	18.26%

Risk and Volatility

ZimVie has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, biote has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Summary

biote beats ZimVie on 9 of the 14 factors compared between the two stocks.

About ZimVie

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.